The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Share News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 19.25
Bid: 19.00
Ask: 19.50
Change: 0.00 (0.00%)
Spread: 0.50 (2.632%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 19.25
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: Retailers Next and JD Sports bookend FTSE 100

Thu, 04th Jan 2024 12:09

(Alliance News) - Stock prices in London were slightly higher at midday on Thursday, with the FTSE 100 looking set to snap the two-day losing streak it suffered at the start of the year.

Retailers Next and JD Sports were the best and worst performing blue-chip stocks respectively, after both provided trading updates including the Christmas period.

US stocks were called to open higher, following the release of minutes from the latest Federal Reserve meeting, and before the first of a pair of monthly US employment readings on Thursday.

The FTSE 100 index was up 7.08, or 0.1%, at 7,689.41. The FTSE 250 was up 14.33 points, 0.1%, at 19,340.73, and the AIM All-Share was up 0.28 of a point, marginally up, at 754.34.

The Cboe UK 100 was up 0.1% at 767.56, the Cboe UK 250 was up 0.2% at 16,806.97, and the Cboe Small Companies was up 0.4% at 14,916.62.

The UK service economy had its best performance in six months in December, a strong end to the year which helped boost the wider private sector, numbers showed.

The final S&P Global UK services business activity index climbed to 53.4 points in December from 50.9 in November. This was above the 50.0 no-change mark for the second month running and above the earlier flash estimate of 52.7

The final seasonally adjusted S&P Global UK composite purchasing managers' index registered 52.1 points in December, up from 50.7 in November and above the neutral 50.0 value for the second month running. This beat last month's flash estimate for December of 51.7 points and marked the highest final reading since June.

"The further rebound in December's PMI suggests a recession should be narrowly avoided," said Pantheon Macroeconomics analyst Gabriella Dickens.

In European equities on Thursday, the CAC 40 in Paris was up 0.4%, while the DAX 40 in Frankfurt was up 0.3%.

The eurozone service sector's decline slowed marginally in December, according to survey data from S&P Global.

The latest HCOB services purchasing managers' index posted 48.8 points in December, rising marginally from 48.7 in November and marking the fifth consecutive monthly contraction. The figure remained below the 50-point no-change mark, but registered above the flash estimate of 48.1 points.

S&P Global said demand for services fell at the end of the year, while sales and new business receipts also declined.

The HCOB eurozone composite PMI - a weighted average of the eurozone's manufacturing and services PMIs - posted 47.6 points in December, unchanged from November, and remaining below the 50-point threshold.

Sterling was quoted at USD1.2705 at midday on Thursday, higher than USD1.2646 at the London equities close on Wednesday. The euro traded at USD1.0958, higher than USD1.0915. Against the yen, the dollar was quoted at JPY144.19, up from JPY143.50.

In the FTSE 100, Next rose 4.7%. The retailer said full price sales during November and December were better than it anticipated.

In a trading update covering the nine weeks to December 30, Next said full price sales were up 5.7% from a year earlier, which was GBP39 million than its previous guidance of a 2.0% rise for the period.

Next upped its full-year pretax profit guidance by GBP20 million, or 4.0% to GBP905 million compared to last year, saying GBP17 million of the lift comes from the sales beat to date and GBP3 million from an upgraded forecast for full price sales in January.

JD Sports plunged 23%, after cutting its profit outlook amid weaker-than-expected sales growth and gross margins.

The retailer said organic revenue was up 6.0% in the 22 weeks that ended December 30 on a constant currency basis from a year earlier, with like-for-like growth of 1.8%. This was slightly behind its expectations. The retailer expects organic revenue growth of around 8% for the year ending February 3.

As a result, it expects to report pretax profit and adjusted items of between GBP915 million and GBP935 million for the financial year. This falls short of market expectations of GBP1.04 billion, which back in September, JD Sports had said it expected to meet.

"Our key markets have seen increased promotional activity during the peak trading season, driven by a more cautious consumer, but we continue to grow market share," said JD Sports Chief Executive Officer Regis Schultz.

"We are confident in our strategy and we continue to invest in our supply chain, systems and stores, supported by our strong cash generation and healthy balance sheet."

Oil majors BP and Shell rose 1.8% and 0.9% respectively, tracking higher oil prices. Brent oil bought USD78.87 a barrel early Thursday, higher than USD78.13 on Wednesday, as traders assess latest developments in the Middle East.

"The region remains a tinder box due to the Israel-Gaza war, and disruption to shipping routes through the Red Sea is also a key factor behind the surge in crude," AJ Bell analyst Russ Mould commented.

Among London's small-cap stocks, Topps Tiles lost 7.0%.

The retailer said sales in the 13 weeks ended December 30 were down 4.0% from a year earlier, with like-for-like sales down 7.1%.

It explained that trading in the first quarter reflected the ongoing challenges to discretionary consumer spending, particularly those impacting on businesses serving the repair, maintenance and improvement sector.

Topps Tiles expects its full-year profit to be weighted towards the second half, based on a number of factors including the timing of the holiday pay accrual, higher energy usage in the first half and general trading in the first half.

On AIM, Angle soared 66%, after it unveiled "breakthrough" clinical results from DNA molecular analysis of cancer patient blood samples that "provide a unique insight into the progression of each patient's cancer and how this may be treated".

The medical diagnostics firm said the results "highlight the potential for the Parsortix system to identify key variants [of] DNA mutations missed by other approaches to help guide treatment decisions."

Stocks in New York were called higher. The Dow Jones Industrial Average, the S&P 500 index up and the Nasdaq Composite were all called up 0.2%.

On the US data calendar on Thursday, there is the ADP jobs report at 1315 GMT, a precursor to Friday's nonfarms. The latest initial jobless claims reading is at 1330 GMT, before a services PMI at 1445 GMT.

The data comes after minutes from the Federal Reserve's latest meeting were released overnight.

"Yesterday's FOMC minutes brought a little bit of something for everyone, with members expressing caution as they attempt to drive inflation back down to target. While they currently do not see any upside risk to inflation, there is a concern that they could stall the current disinflation should they pivot too swiftly. Nonetheless, the key takeaway is that they are looking at the six-month metric for the core PCE, which has already dropped below 2%," Scope Markets analyst Joshua Mahony commented.

"With that in mind, markets have remained highly dovish, expecting a whopping six rate cuts this year from the Fed. All eyes will now turn towards the US employment data, with today's ADP payrolls figure leading into tomorrow's jobs report. With Fed member Barkin speculating that a soft-landing looks increasingly likely, a gradual deterioration in the payrolls and unemployment rate could help put pressure on the FOMC to cut rates in March."

Gold was quoted at USD2,047.78 an ounce at midday on Thursday, higher than USD2,038.89 on Wednesday.

By Greg Rosenvinge, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
22 Jul 2019 12:53

Angle's Parsortix Used For Analysis Of Circulating Tumor Cells

(Alliance News) - Angle PLC on Monday said one of its leading customers, the Disseminated Cancer Cell Network, has published new results of work done to develop a "robust, reliable and for of

Read more
25 Jun 2019 08:16

Angle looks to strengthen balance sheet and extend runway via placement

(Sharecast News) - Liquid biopsy company Angle will look to raise up £18m at 61.5p per ordinary share through finnCap and WG Partners in order to strengthen its balance sheet and enable the development of key products.

Read more
21 Jun 2019 15:26

Angle upbeat on recent cancer research results

(Sharecast News) - Liquid biopsy company Angle announced on Friday that the University Medical Centre Hamburg-Eppendorf (UKE) cancer centre has published results of work demonstrating that its 'Parsortix' system can be used as a liquid biopsy to investigate programmed death-ligand 1 (PD-L1) status in non small cell lung cancer (NSCLC) patients.

Read more
21 Jun 2019 12:56

Angle's Parsortix Successfully Investigates Immunotherapy Target

(Alliance News) - Angle PLC on Friday said its Parsortix system has been successfully used as a liquid biopsy to investigate an immunotherapy target in lung cancer.Shares in Angle were up a

Read more
5 Jun 2019 13:04

Angle's Parsortix And HyCEAD Ziplex Systems Identify Cancer In Study

LONDON (Alliance News) - Angle PLC on Wednesday announced positive results from a study evaluating the ability of its Parsortix and HyCEAD Ziplex platforms to test for ovarian cancer.The to

Read more
31 May 2019 09:53

Angle reveals positive results from latest Parsortix study

(Sharecast News) - Liquid biopsy company Angle announced positive results from its 'Parsortix' FDA clinical study for metastatic breast cancer on Friday.

Read more
26 Apr 2019 12:48

Angle's Parsortix system used in more groundbreaking research

(Sharecast News) - Liquid biopsy company Angle announced on Friday that its 'Parsortix' system has been utilised in further groundbreaking new cancer research, demonstrating the role of myeloid-derived suppressor cells (MDSCs) as part of large circulating tumor cell (CTC) clusters, which are 50x more likely to generate metastasis than single CTCs, for the first time.

Read more
26 Apr 2019 12:29

Angle's Parsortix System Used In Further "Groundbreaking" Research

LONDON (Alliance News) - Liquid biopsy firm Angle PLC on Friday said its Parsortix system has been used in "groundbreaking" cancer research.The research showed the first the time

Read more
18 Apr 2019 11:35

US Cancer Centre Uses Angle's Parsortix System For Assessments

LONDON (Alliance News) - Angle PLC on Thursday said its ParsortixTM system was used by the University of Texas MD Anderson Cancer Center to develop a new technique for assessing the metastatic of

Read more
12 Apr 2019 15:25

Angle's Parsortix to be used in new Greece study

(Sharecast News) - Liquid biopsy company Angle announced on Friday that a leading customer has established a multi-centre study to investigate biomarkers on circulating tumor cells (CTCs), using its 'Parsortix' system, which could give advance warning of relapse in non small cell lung cancer (NSCLC).

Read more
12 Apr 2019 11:59

University Of Athens Cancer Study To Use Angle's Parsortix System

LONDON (Alliance News) - Liquid biopsy firm Angle PLC on Friday said a "leading" customer has set up a multi-centre study using its Parsortix system.The study is being carried out

Read more
7 Mar 2019 13:09

Angle Enrols All 400 Patients In US Breast Cancer Study For Parsortix

LONDON (Alliance News) - Angle PLC on Thursday said it has completed enrolment for a US study of its Parsortix biopsy technology in metastatic breast cancer.All of the 400 subjects required

Read more
7 Mar 2019 09:35

Angle completes enrolment in Parsortix breast cancer study

(Sharecast News) - Liquid biopsy company Angle announced on Thursday that enrolment for its 'Parsortix' FDA clinical study for metastatic breast cancer was now complete.

Read more
28 Feb 2019 13:30

Angle Enrolls First Patients In Ovarian Cancer Study

LONDON (Alliance News) - Angle PLC on Thursday said it has enrolled the first patients in an ovarian cancer verification study, after receiving ethics approval.The study will be divided a a

Read more
25 Feb 2019 10:51

Angle client demonstrates new use for 'Parsortix' system

(Sharecast News) - Liquid biopsy company Angle said on Monday that one of its leading customers, the Disseminated Cancer Cell Network (DCCNet) in Duesseldorf, has published new results in a peer-reviewed journal of work done to harvest circulating tumor cells (CTCs) from diagnostic leukapheresis (DLA) samples.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.